Oral anti-CD3 mAb: Phase IIa started

NasVax began a single-blind, placebo-controlled, Israeli Phase IIa trial to evaluate once-daily 0.2, 1 and 5 mg doses of its oral anti-CD3 mAb immunotherapy for 30 days in about 36 patients with NASH....